You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Not Available
Identification
Name4-Bromo-2,5-dimethoxyamphetamine
Accession NumberDB01484
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS number32156-26-6
WeightAverage: 274.154
Monoisotopic: 273.036441408
Chemical FormulaC11H16BrNO2
InChI KeyFXMWUTGUCAKGQL-UHFFFAOYSA-N
InChI
InChI=1S/C11H16BrNO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
IUPAC Name
1-(4-bromo-2,5-dimethoxyphenyl)propan-2-amine
SMILES
COC1=CC(Br)=C(OC)C=C1CC(C)N
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Acrivastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Acrivastine.Approved
Alcaftadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Alcaftadine.Approved
Alfentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
Alimemazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
Alphacetylmethadol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Aluminum phosphateAluminum phosphate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Ammonium chlorideThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
Antazoline4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Astemizole4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Vet Approved
Azatadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Azatadine.Approved
Azelastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Azelastine.Approved
BenmoxinBenmoxin may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Bezitramide4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
BromperidolBromperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Brompheniramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Brompheniramine.Approved
Buclizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Buclizine.Approved
Buprenorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
Butanoic Acid4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Butanoic Acid.Experimental
Butorphanol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium carbonateCalcium carbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Carbinoxamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Carbinoxamine.Approved
Carfentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Cetirizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cetirizine.Approved
Chloropyramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chloropyramine.Approved
Chlorphenamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenamine.Approved
Chlorphenoxamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorpromazineChlorpromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Withdrawn
Cimetidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cimetidine.Approved
Cinnarizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cinnarizine.Approved
Clemastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
ClozapineClozapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Codeine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Cyclizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Cyproheptadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
DesipramineDesipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Desloratadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
Dexbrompheniramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine maleate4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
Dextromoramide4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
Dextropropoxyphene4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
Dezocine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dezocine.Approved
DiclofenamideDiclofenamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Dihydrocodeine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Dihydroetorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
Dihydromorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
Dimenhydrinate4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
Dimetindene4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimetindene.Approved
Dimetotiazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Dimetotiazine.Approved
Diphenhydramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Diphenhydramine.Approved
Diphenoxylate4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DosulepinDosulepin may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Doxepin4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxepin.Approved
Doxylamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPE4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of DPDPE.Investigational
DroperidolDroperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
Ebastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Emedastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Emedastine.Approved
Epinastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
Esmirtazapine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Esmirtazapine.Investigational
Ethopropazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Withdrawn
Ethylmorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
Etorphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
Famotidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Illicit, Withdrawn
Fentanyl4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fexofenadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Fexofenadine.Approved
Flunarizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
GuanethidineThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Heroin4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Heroin.Approved, Illicit
HexamethylenetetramineThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Hexamethylenetetramine.Approved, Vet Approved
HydracarbazineHydracarbazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Hydrocodone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Hydromorphone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
Hydroxyzine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ImipramineImipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Ioflupane I-1234-Bromo-2,5-dimethoxyamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Isothipendyl4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Isothipendyl.Approved
Kct 08094-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Kct 0809.Investigational
Ketobemidone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Ketobemidone.Approved
Ketotifen4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ketotifen.Approved
L-Glutamic AcidThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with L-Glutamic Acid.Nutraceutical
Levocabastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Levocabastine.Approved
Levocetirizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl Acetate4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved
Levorphanol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Lodoxamide4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Lodoxamide.Approved
Lofentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Lofentanil.Illicit
Loratadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Meclizine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Mepyramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
Mequitazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Methadone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Methadone.Approved
Methadyl Acetate4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
Methapyrilene4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Metiamide4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Metiamide.Experimental
Mianserin4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mianserin.Approved
MinaprineMinaprine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Mirtazapine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mirtazapine.Approved
Mizolastine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Morphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
Nalbuphine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Nizatidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Nizatidine.Approved
Normethadone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Olopatadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Opium4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Oxycodone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
Oxymorphone4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PargylinePargyline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Pemirolast4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Pemirolast.Approved
Pentazocine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Pethidine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Pethidine.Approved
PhenelzinePhenelzine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Phenindamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
Pheniramine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with 4-Bromo-2,5-dimethoxyamphetamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PipamperonePipamperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Piritramide4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
ProchlorperazineProchlorperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
Promethazine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
RacloprideRaclopride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Ranitidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Remifentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
Roxatidine acetate4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Withdrawn
SelegilineSelegiline may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Withdrawn
Spaglumic Acid4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Spaglumic Acid.Approved
Sufentanil4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Tapentadol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Tapentadol.Approved
Terfenadine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Terfenadine.Withdrawn
Tesmilifene4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tesmilifene.Investigational
ThioproperazineThioproperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ThiothixeneThiothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Thonzylamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
TiaprideTiapride may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Investigational
ToloxatoneToloxatone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Tramadol4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
Tranilast4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
TriflupromazineTriflupromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
Tripelennamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
Triprolidine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Triprolidine.Approved
Vitamin CThe serum concentration of 4-Bromo-2,5-dimethoxyamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ZotepineZotepine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9962
Blood Brain Barrier+0.9475
Caco-2 permeable+0.7137
P-glycoprotein substrateNon-substrate0.711
P-glycoprotein inhibitor INon-inhibitor0.804
P-glycoprotein inhibitor IINon-inhibitor0.9441
Renal organic cation transporterNon-inhibitor0.8015
CYP450 2C9 substrateNon-substrate0.8693
CYP450 2D6 substrateSubstrate0.6261
CYP450 3A4 substrateSubstrate0.5248
CYP450 1A2 substrateInhibitor0.8743
CYP450 2C9 inhibitorNon-inhibitor0.8389
CYP450 2D6 inhibitorInhibitor0.8451
CYP450 2C19 inhibitorNon-inhibitor0.7714
CYP450 3A4 inhibitorNon-inhibitor0.7737
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.5865
CarcinogenicityNon-carcinogens0.7668
BiodegradationNot ready biodegradable0.9808
Rat acute toxicity3.0047 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8956
hERG inhibition (predictor II)Non-inhibitor0.617
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.58HANSCH,C & LEO,AJ (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.0948 mg/mLALOGPS
logP2.53ALOGPS
logP2.26ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)9.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity64.25 m3·mol-1ChemAxon
Polarizability25.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • P-dimethoxybenzene
  • Dimethoxybenzene
  • Amphetamine or derivatives
  • Phenylpropane
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Halobenzene
  • Bromobenzene
  • Alkyl aryl ether
  • Aryl halide
  • Aryl bromide
  • Ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organobromide
  • Organohalogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on July 31, 2007 07:09 / Updated on August 17, 2016 12:23